JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1603-1612

  Guma, Monica ^a   Ronacher, Lisa M ^a   Firestein, Gary S ^a   Karin, Michael ^a   Corr, Maripat ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PROTEIN JNK 1; PROTEIN JNK 2; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; JOINT DESTRUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; BONE MARROW; CELL MOVEMENT; CHIMERA; CYTOKINES; FEMALE; FREUND'S ADJUVANT; IMMUNOGLOBULINS; KNEE JOINT; MACROPHAGES; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PEPTIDES; SERUM ALBUMIN, BOVINE; T-LYMPHOCYTES; THIOGLYCOLATES; ZYMOSAN;

EID: 79958064088     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30271     Document Type: Article

References (42)

1. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61. (Pubitemid 40852711)
2. Van Vollenhoven RF,. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-41.
3. Hammaker D, Firestein GS,. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 Suppl I: i77-82.
4. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
5. Dong C, Davis RJ, Flavell RA,. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72. (Pubitemid 34293420)
6. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-83. (Pubitemid 32458157)
7. Sweeney SE, Firestein GS,. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006; 65 Suppl III: iii83-8. (Pubitemid 44629110)
8. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS,. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999; 291: 124-30. (Pubitemid 29451581)
9. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81. (Pubitemid 32634924)
10. Karin M, Gallagher E,. From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005; 57: 283-95. (Pubitemid 40904256)
11. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M,. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci U S A 2009; 106: 8760-5.
12. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K,. JNK phosphorylates paxillin and regulates cell migration. Nature 2003; 424: 219-23. (Pubitemid 36858692)
13. Davis RJ,. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
14. Koller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, et al. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 2005; 7: R166-73.
15. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS,. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 818-23. (Pubitemid 34214265)
16. Bain J, McLauchlan H, Elliott M, Cohen P,. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371: 199-204. (Pubitemid 36458094)
17. Tanemura S, Momose H, Shimizu N, Kitagawa D, Seo J, Yamasaki T, et al. Blockage by SP600125 of Fcε receptor-induced degranulation and cytokine gene expression in mast cells is mediated through inhibition of phosphatidylinositol 3-kinase signalling pathway. J Biochem 2009; 145: 345-54.
18. Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, Jochum W, et al. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol 1999; 9: 116-25. (Pubitemid 29087541)
19. Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF,. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med 2001; 193: 317-28. (Pubitemid 32524515)
20. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M,. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60: 3642-50.
21. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-6. (Pubitemid 37173703)
22. Dong C, Yang DD, Tournier C, Whitmarsh AJ, Xu J, Davis RJ, et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405: 91-4. (Pubitemid 30321821)
23. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA,. Defective T cell differentiation in the absence of Jnk1. Science 1998; 282: 2092-5. (Pubitemid 29001267)
24. Tran EH, Azuma YT, Chen M, Weston C, Davis RJ, Flavell RA,. Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain. Proc Natl Acad Sci U S A 2006; 103: 13451-6. (Pubitemid 44380128)
25. Sukhumavasi W, Egan CE, Denkers EY,. Mouse neutrophils require JNK2 MAPK for Toxoplasma gondii-induced IL-12p40 and CCL2/MCP-1 release. J Immunol 2007; 179: 3570-7.
26. 2 terminal kinase. J Leukoc Biol 2010; 87: 925-32.
27. Sodhi A, Biswas SK,. Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation. J Interferon Cytokine Res 2002; 22: 517-26. (Pubitemid 34639142)
28. L turnover. Cell 2006; 124: 601-13. (Pubitemid 43199444)
29. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6. (Pubitemid 38198821)
30. Szekanecz Z, Koch AE,. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-95. (Pubitemid 46597469)
31. Brennan F, Beech J,. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296-301. (Pubitemid 46597470)
32. Richards PJ, Williams AS, Goodfellow RM, Williams BD,. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999; 38: 818-25. (Pubitemid 29507362)
33. Lawlor KE, Wong PK, Campbell IK, van Rooijen N, Wicks IP,. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. Arthritis Rheum 2005; 52: 3749-54. (Pubitemid 41798211)
34. Van de Loo AA, Arntz OJ, Bakker AC, van Lent PL, Jacobs MJ, van den Berg WB,. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995; 146: 239-49.
35. Van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, van de Putte LB, et al. Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001; 159: 2309-20. (Pubitemid 33104284)
36. Van Lent PL, van Vuuren AJ, Blom AB, Holthuysen AE, van de Putte LB, van de Winkel JG, et al. Role of Fc receptor γ chain in inflammation and cartilage damage during experimental antigen-induced arthritis. Arthritis Rheum 2000; 43: 740-52.
37. Volin MV, Huynh N, Klosowska K, Reyes RD, Woods JM,. Fractalkine-induced endothelial cell migration requires MAP kinase signaling. Pathobiology 2010; 77: 7-16.
38. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2387-92. (Pubitemid 44204998)
39. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008; 58: 1931-9. (Pubitemid 351988084)
40. Iwamoto T, Okamoto H, Toyama Y, Momohara S,. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008; 275: 4448-55.
41. Murphy G, Caplice N, Molloy M,. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford) 2008; 47: 1446-51.
42. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ,. Induction of hepatitis by JNK-mediated expression of TNF-α. Cell 2009; 136: 249-60.